Beijing Tong Ren Tang Chinese Medicine Company Limited (3613.HK)
HKD 8.37
(-0.95%)
HKD 8.37
(-0.95%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 779.54 Million HKD | -23.48% |
| 2022 | 907.63 Million HKD | 6.04% |
| 2021 | 852.8 Million HKD | 12.02% |
| 2020 | 769.14 Million HKD | -0.57% |
| 2019 | 774.64 Million HKD | 2.78% |
| 2018 | 728.31 Million HKD | 17.81% |
| 2017 | 630.96 Million HKD | 14.41% |
| 2016 | 557.75 Million HKD | 16.19% |
| 2015 | 480.04 Million HKD | 32.73% |
| 2014 | 361.65 Million HKD | 27.5% |
| 2013 | 288.5 Million HKD | 126.67% |
| 2012 | 123.71 Million HKD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 134.09 Million HKD | -10.88% |
| 2024 Q2 | 134.09 Million HKD | 0.0% |
| 2023 Q1 | 169.02 Million HKD | -34.85% |
| 2023 FY | - HKD | -23.48% |
| 2023 Q3 | 150.45 Million HKD | -10.99% |
| 2023 Q2 | 169.02 Million HKD | 0.0% |
| 2023 Q4 | 150.45 Million HKD | 0.0% |
| 2022 Q3 | 259.43 Million HKD | -20.41% |
| 2022 Q4 | 259.43 Million HKD | 0.0% |
| 2022 Q1 | 149.98 Million HKD | -67.61% |
| 2022 Q2 | 325.98 Million HKD | 117.34% |
| 2022 FY | - HKD | 6.04% |
| 2021 FY | - HKD | 12.02% |
| 2021 Q2 | 377.5 Million HKD | 112.97% |
| 2021 Q3 | 215.99 Million HKD | -42.78% |
| 2021 Q4 | 462.99 Million HKD | 114.35% |
| 2021 Q1 | 177.25 Million HKD | -58.44% |
| 2020 Q1 | 137.69 Million HKD | -48.98% |
| 2020 Q2 | 295.41 Million HKD | 114.55% |
| 2020 Q3 | 195.41 Million HKD | -33.85% |
| 2020 FY | - HKD | -0.57% |
| 2020 Q4 | 426.5 Million HKD | 118.26% |
| 2019 Q4 | 269.85 Million HKD | 122.65% |
| 2019 Q2 | 460.08 Million HKD | 110.32% |
| 2019 Q1 | 218.75 Million HKD | 29.32% |
| 2019 Q3 | 121.2 Million HKD | -73.66% |
| 2019 FY | - HKD | 2.78% |
| 2018 Q4 | 169.16 Million HKD | 0.0% |
| 2018 Q3 | 169.16 Million HKD | -10.27% |
| 2018 Q2 | 188.51 Million HKD | -3.72% |
| 2018 FY | - HKD | 17.81% |
| 2018 Q1 | 195.78 Million HKD | 44.9% |
| 2017 Q3 | 154.82 Million HKD | 2.66% |
| 2017 FY | - HKD | 14.41% |
| 2017 Q2 | 150.81 Million HKD | -11.44% |
| 2017 Q4 | 135.11 Million HKD | -12.73% |
| 2017 Q1 | 170.28 Million HKD | 54.86% |
| 2016 Q4 | 109.96 Million HKD | -17.72% |
| 2016 FY | - HKD | 16.19% |
| 2016 Q3 | 133.63 Million HKD | -10.89% |
| 2016 Q2 | 149.97 Million HKD | 8.1% |
| 2016 Q1 | 138.73 Million HKD | 13.77% |
| 2015 Q2 | 117.31 Million HKD | 12.75% |
| 2015 Q4 | 121.94 Million HKD | 9.91% |
| 2015 Q3 | 110.94 Million HKD | -5.43% |
| 2015 Q1 | 104.05 Million HKD | 11.66% |
| 2015 FY | - HKD | 32.73% |
| 2014 Q3 | 80.57 Million HKD | -10.87% |
| 2014 Q2 | 90.4 Million HKD | 13.92% |
| 2014 Q1 | 79.35 Million HKD | -14.5% |
| 2014 FY | - HKD | 27.5% |
| 2014 Q4 | 93.18 Million HKD | 15.65% |
| 2013 Q1 | 46.3 Million HKD | 0.19% |
| 2013 FY | - HKD | 126.67% |
| 2013 Q2 | 70.55 Million HKD | 52.38% |
| 2013 Q3 | 58.57 Million HKD | -16.98% |
| 2013 Q4 | 92.82 Million HKD | 58.46% |
| 2012 FY | - HKD | 0.0% |
| 2012 Q4 | 46.21 Million HKD | 38.99% |
| 2012 Q1 | 13.37 Million HKD | 0.0% |
| 2012 Q2 | 20.82 Million HKD | 55.68% |
| 2012 Q3 | 33.24 Million HKD | 59.63% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| China Healthwise Holdings Limited | -117.45 Million HKD | 763.716% |
| Tycoon Group Holdings Limited | 147.38 Million HKD | -428.915% |